Palchaudhuri, Rahul
Saez, Borja
Hoggatt, Jonathan
Schajnovitz, Amir
Sykes, David B
Tate, Tiffany A
Czechowicz, Agnieszka
Kfoury, Youmna
Ruchika, FNU
Rossi, Derrick J
Verdine, Gregory L
Mansour, Michael K
Scadden, David T
Article History
Received: 16 February 2016
Accepted: 27 April 2016
First Online: 6 June 2016
Competing interests
: The authors declare relevant competing financial interests as follows. Magenta Therapeutics, equity and consulting: R.P., J.H., A.C., D.J.R., and D.T.S. Fate Therapeutics, equity and consulting: D.T.S.; consulting: J.H. GlaxoSmithKline, consulting and sponsored research: J.H. and D.T.S. Intellia Therapeutics, equity and consulting: D.J.R. Moderna Therapeutics, equity: D.J.R. Inventors, US patent applications (US 62/143,642; US 62/220,204; US 62/221,595; and US 62/239,573): R.P. and D.T.S.